Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
The purpose of this study is to assess the effects of hepatic impairment on the single dose
 pharmacokinetics of BMS-790052.
Key Inclusion Criteria:

 -  Male and female subjects aged 18 to 70 years, with hepatic impairment conforming to
 Child-Pugh class A, B or C

 -  Healthy subjects to the extent possible matched to the first four hepatically impaired
 subject in each Child-Pugh class with regard to age (approximately ± 10 years), body
 weight (approximately ± 20%) and gender

 Key Exclusion Criteria:

 -  History of esophageal and gastric variceal bleeding within past 6 months

 -  Primarily cholestatic liver diseases

 -  Active alcoholic hepatitis

 -  Stable encephalopathy of >= Stage 2

 -  Presence of severe ascites or edema

 -  Presence of hepatopulmonary or hepatorenal syndrome

 -  Positive for HCV, unless HCV RNA is undetectable